Baxter International Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BAX research report →
Range $20 – $28
Price Chart
About the company
Baxter International Inc. , operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services.
- CEO
- Andrew Hider
- IPO
- 1981
- Employees
- 37,500
- HQ
- Deerfield, IL, US
Get TickerSpark's AI analysis on BAX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $13.14B
- P/E
- -18.40
- Fwd P/E
- 12.06
- PEG
- 0.10
- P/S
- 1.13
- P/B
- 2.02
- EV/EBITDA
- 24.90
- Div Yield
- 0.16%
- Gross Margin
- 30.09%
- Op Margin
- -1.90%
- Net Margin
- -6.23%
- ROE
- -11.62%
- ROIC
- -1.34%
Latest fiscal year · YoY change
- Revenue
- $11.24B+5.7%
- Gross Profit
- $3.38B-15.2%
- Op Income
- $-308,000,000
- Net Income
- $-957,000,000-47.5%
- EPS
- $-1.75-37.8%
- OCF Growth
- -17.1%
- FCF Growth
- -42.2%
- 52W High
- $30.00
- 52W Low
- $15.73
- 50D MA
- $24.61
- 200D MA
- $21.75
- Beta
- 0.67
- RSI (14)
- 54
- Avg Volume
- 6.38M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Baxter said its turnaround is gaining traction, with Q3 sales, EPS and cash flow ahead of expectations and full-year outlook raised.· October 29, 2026
- Q3 global sales were about $3 billion, up 5% reported and organic, with adjusted EPS of $0.58 per share.
- Full-year organic sales growth guidance was raised to 3% to 4%, and adjusted EPS guidance was narrowed higher to $2.05 to $2.15.
- Free cash flow was strong at $448 million in Q3 and $705 million year to date, helped by working capital discipline and cash receipts.
- Baxter is discontinuing cephalosporin production at Round Lake; management said it should not cause a market shortage and will simplify operations.
- Advanced Surgery, Drug Compounding and Infusion Systems were key growth drivers, while injectables remained a drag from pricing and manufacturing issues.
Third quarter 2026 global sales were approximately $3 billion, up 5% on both a reported and organic basis. Adjusted earnings were $0.58 per diluted share, down 16% year over year, reflecting a higher effective tax rate versus prior-year discrete tax benefits. Adjusted gross margin was 38.3%, down 110 basis points; adjusted operating margin was 14.5%, down 40 basis points. Free cash flow was $448 million in Q3 and $705 million year to date. For full-year 2026, Baxter now expects reported sales growth of 4% to 5%, organic sales growth of 3% to 4%, adjusted operating margin of 13% to 14%, nonoperating expenses of $245 million to $255 million, a tax rate of 18.5% to 19.5%, and adjusted EPS of $2.05 to $2.15 per diluted share. Segment guidance includes MPT organic sales growth of low to mid-single digits and HST organic sales growth of low single digits.
Andrew Hider framed the quarter as evidence that Baxter's turnaround is gaining traction and said the company delivered results ahead of expectations. He emphasized progress on the three priorities: stabilizing operations, strengthening the balance sheet, and embedding continuous improvement through Baxter GPS. His tone was constructive but measured, stressing that there is still a lot of work ahead and that the company must keep improving execution consistency.
John Rogers highlighted Q3 sales of approximately $3 billion, adjusted EPS of $0.58, free cash flow of $448 million, and year-to-date free cash flow of $705 million. He said the $600 million cash tender offer retired $864 million of debt and supported Baxter's confidence in reaching approximately 3x net leverage by year-end. On margins, he cited adjusted gross margin of 38.3% and adjusted operating margin of 14.5%, and said the updated outlook reflects lower interest expense, stronger organic growth, and continued pressure from mix, pricing, taxes and other moving parts. He also pointed to inflationary pressure in 2027, particularly salary inflation, electronics and materials, while noting a pipeline of savings opportunities.
Analysts focused heavily on the Round Lake warning letter, the cephalosporin discontinuation, and whether the move creates 2027 earnings headwinds; management said the change simplifies operations, supports supply resiliency, and helps address warning-letter complexity, while noting there will be offsets and the net 2027 impact is still being evaluated. Questions also centered on M&A, and Andrew Hider said Baxter will apply a disciplined framework around strategic fit, market opportunity, integration capability and financial returns, with a preference for tuck-in deals now that leverage is trending toward the 3x target. Other topics included 2027 margins, tariffs, inflation, and the contract manufacturer issue; management repeatedly declined to quantify 2027 impacts now, but said it expects both headwinds and offsetting savings opportunities, and that the contract-manufacturer supply issue is improving.
The call showed momentum across the portfolio, with broad-based sales growth, a stronger second-half margin profile and free cash flow improving meaningfully. Management sounded increasingly confident in operational execution, cited better quality and shipment metrics, and raised full-year guidance after Q3 exceeded expectations.
Management flagged several 2027 headwinds still under review, including TSA roll-off, inflation, tariffs, planned product exits and the cephalosporin discontinuation. Injectables still face pricing and manufacturing pressure, and Baxter is also dealing with a recent FDA warning letter tied to Round Lake, even though management says the site changes should help address it.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.4%
- Shares Outstanding
- 517.35M
- Float Shares
- 514.04M
of shares held by institutions
726 13F filers
Congressional trading
Senate and House stock disclosures for BAX, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Buy | May 1, 26 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Mar 23, 26 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Jan 13, 26 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Oct 31, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Oct 30, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Oct 30, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Sep 25, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 5, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 29, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 3, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Aug 4, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Aug 26, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Aug 12, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Aug 4, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 65.54M | ▼ 16.30M |
| Vanguard Group Inc | 62.64M | ▲ 109.50K |
| Pzena Investment Management LLC | 62.43M | ▼ 2.87M |
| Dodge & Cox | 55.65M | ▼ 2.73M |
| Fmr LLC | 51.46M | ▼ 2.45M |
| Vanguard Capital Management LLC | 33.91M | ▲ 151.70K |
| Vanguard Portfolio Management LLC | 23.41M | ▼ 642.34K |
| State Street Corp | 20.62M | ▲ 24.41K |
| Geode Capital Management, LLC | 13.93M | ▼ 191.30K |
| Greenhaven Associates Inc | 12.40M | ▼ 1.89M |
| Invesco Ltd. | 11.30M | ▼ 1.06M |
| Morgan Stanley | 7.76M | ▲ 1.40M |
Held by 967 ETFs
Biggest fund positions in BAX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | Rogers Terence John | other | 0 |
| Sep 15, 26 | Heine Bernard | other | 0 |
| Sep 1, 26 | Teaff James | other | 750 |
| Sep 2, 26 | Hider Andrew P. | other | 54,276 |
| Sep 2, 26 | Foster Julie | other | 2,098 |
| May 5, 26 | Wilkes David S. | other | 12,836 |
| May 5, 26 | Wendell Amy McBride | other | 12,836 |
| May 5, 26 | SCHLICHTING NANCY M | other | 12,836 |
| May 5, 26 | MORRISON PATRICIA | other | 12,836 |
| May 5, 26 | Shafer David Brent | other | 12,836 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BAX coverage
Recent articles, reports, and earnings notes.
No research on BAX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BAX report →Baxter: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 18
Chicago Partners Investment Group LLC Purchases New Stake in Baxter International Inc. $BAX
defenseworld.net · Nov 12
International Assets Investment Management LLC Acquires 72,405 Shares of Baxter International Inc. $BAX
defenseworld.net · Nov 3
What Baxter International (BAX) Said on Its Q3 Earnings Call
marketbeat.com · Oct 30
Baxter Q3 Earnings Beat on Broad-Based Growth, '26 Outlook Raised
zacks.com · Oct 29
Baxter International Inc. (BAX) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 29
Why Is Baxter Stock Trading Lower on Thursday?
benzinga.com · Oct 29
Compared to Estimates, Baxter (BAX) Q3 Earnings: A Look at Key Metrics
zacks.com · Oct 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.